Blindness News and Research

RSS

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Spark Therapeutics and Genable Technologies announced today that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038.

25 Mar 2014

Researchers developing new medication to tackle river blindness and elephantiasis

Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.

24 Mar 2014

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics Limited is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial.

24 Mar 2014

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.

20 Mar 2014

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.

20 Mar 2014

TVM Capital Healthcare Partners signs affiliation with Joslin Diabetes Center

TVM Capital Healthcare Partners, the region's first private equity firm dedicated exclusively to the healthcare sector, has signed an affiliation with Joslin Diabetes Center.

17 Mar 2014

Driving simulator may help people with hemianopia to drive safely

A diagnosis of hemianopia, or blindness in one half of the visual field in both eyes as the result of strokes, tumors or trauma often means the end of driving.

17 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Eye health experts across Commonwealth join forces to combat avoidable blindness

A new -7.1 million grant will enable experts from a range of institutions to come together for the first time as the Commonwealth Eye Health Consortium, coordinated by the International Centre for Eye Health at the London School of Hygiene & Tropical Medicine.

10 Mar 2014

Aetna honored with 2014 Innovation in Reducing Health Care Disparities Award

Aetna was honored today by the National Business Group on Health (NBGH) with the 2014 Innovation in Reducing Health Care Disparities Award. Aetna is a three-time recipient of the award that recognizes organizations for their commitment to equality in health care and exceptional support for cultural diversity.

8 Mar 2014

Research explores new diagnostic strategies to detect glaucoma

Research exploring several new diagnostic strategies to find the earliest changes in the eye to detect glaucoma is underway at the University of Alabama at Birmingham School of Optometry. One optometrist says awareness of this eye disorder is just as important as continuing to study it.

7 Mar 2014

Cataract surgery followed by use of contact lenses may be better solution for infants

For adults and children who undergo cataract surgery, implantation of an artificial lens is the standard of care. But a clinical trial suggests that for most infants, surgery followed by the use of contact lenses for several years—and an eventual lens implant—may be the better solution.

7 Mar 2014

NICE guidance influences medical policy towards diabetes prevention nationwide

A team of academics from the University of Leicester has been instrumental in shaping National Institute for Health and Care Excellence (NICE) guidance that will influence medical policy towards diabetes prevention nationwide.

6 Mar 2014

Research discovery advances efforts to replace damaged heart muscle

In a study that began in a pair of infant siblings with a rare heart defect, Johns Hopkins researchers say they have identified a key molecular switch that regulates heart cell division and normally turns the process off around the time of birth. Their research, they report, could advance efforts to turn the process back on and regenerate heart tissue damaged by heart attacks or disease.

4 Mar 2014

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

4 Mar 2014

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare.

3 Mar 2014

Photoreactive compounds open new routes to treatment of neurological diseases

Photoreactive compounds developed by scientists of Ludwig-Maximilians-Universitaet (LMU) in Munich directly modulate nerve-cell function, and open new routes to the treatment of neurological diseases, including chronic pain and certain types of visual impairment.

3 Mar 2014

Study establishes innovative approaches to improve vision of young children with brain tumor

Robert Avery, DO, MSCE, of Children's National Health System and colleagues are establishing innovative approaches with technology and medication to improve the vision of young children who have visual pathway glioma, a type of brain tumor.

3 Mar 2014

UAB launches pilot program to detect earlier stages of glaucoma

Glaucoma is a silent disease. It does not hurt, symptoms are slow to develop, and most people do not notice any loss of vision until it is too late. A project by ophthalmologists at the University of Alabama at Birmingham will examine whether a partnership with community-based optometrists will improve detection and treatment of glaucoma, especially for high-risk populations.

27 Feb 2014

Study suggests simple way for physicians to communicate treatment goals in type 2 diabetes patients

An editorial in a February issue of American Family Physician proposes a simple way for physicians to communicate with patients about the best treatments for diabetes. The "lending a hand" illustration reprioritizes treatment goals, based on research on mortality reduction, to convey that glycemic control is no longer the primary intervention.

24 Feb 2014

Blindness News and Research

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Researchers developing new medication to tackle river blindness and elephantiasis

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

TVM Capital Healthcare Partners signs affiliation with Joslin Diabetes Center

Driving simulator may help people with hemianopia to drive safely

Antares Pharma announces launch of OTREXUP to Dermatologists

Eye health experts across Commonwealth join forces to combat avoidable blindness

Aetna honored with 2014 Innovation in Reducing Health Care Disparities Award

Research explores new diagnostic strategies to detect glaucoma

Cataract surgery followed by use of contact lenses may be better solution for infants

NICE guidance influences medical policy towards diabetes prevention nationwide

Research discovery advances efforts to replace damaged heart muscle

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Photoreactive compounds open new routes to treatment of neurological diseases

Study establishes innovative approaches to improve vision of young children with brain tumor

UAB launches pilot program to detect earlier stages of glaucoma

Study suggests simple way for physicians to communicate treatment goals in type 2 diabetes patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News